Choi et al. reported that scopoletin (0.01%) ameliorates hyperglycemia and hepatic steatosis in HFD- and STZ-induced diabetic mice through suppression of lipid biosynthesis and the TLR4–MyD88 pathways (Choi et al., 2017). The gene discussed is TLR4; the disease is fatty liver disease.